These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24351180)

  • 1. Role of interleukin-1/interleukin-1 receptor antagonist family of cytokines in long-term continuous glucose monitoring in vivo.
    Klueh U; Antar O; Qiao Y; Kreutzer DL
    J Diabetes Sci Technol; 2013 Nov; 7(6):1538-46. PubMed ID: 24351180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of interleukin-1 and interleukin-1 receptor antagonist in short-term glucose sensor function in vivo.
    Klueh U; Liu Z; Feldman B; Kreutzer D
    J Diabetes Sci Technol; 2010 Sep; 4(5):1073-86. PubMed ID: 20920427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents.
    Somm E; Cettour-Rose P; Asensio C; Charollais A; Klein M; Theander-Carrillo C; Juge-Aubry CE; Dayer JM; Nicklin MJ; Meda P; Rohner-Jeanrenaud F; Meier CA
    Diabetologia; 2006 Feb; 49(2):387-93. PubMed ID: 16385385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-1/IL-1ra balance in the brain revisited - evidence from transgenic mouse models.
    Spulber S; Bartfai T; Schultzberg M
    Brain Behav Immun; 2009 Jul; 23(5):573-9. PubMed ID: 19258032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound Biomicroscopic Imaging for Interleukin-1 Receptor Antagonist-Inhibiting Atherosclerosis and Markers of Inflammation in Atherosclerotic Development in Apolipoprotein-E Knockout Mice.
    Li RJ; Sun Y; Wang Q; Yang J; Yang Y; Song L; Wang Z; Luo XH; Su RJ
    Tex Heart Inst J; 2015 Aug; 42(4):319-26. PubMed ID: 26413013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis.
    Corr M; Boyle DL; Ronacher LM; Lew BR; van Baarsen LG; Tak PP; Firestein GS
    Ann Rheum Dis; 2011 May; 70(5):858-63. PubMed ID: 21216819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis.
    Powers NE; Swartzwelter B; Marchetti C; de Graaf DM; Lerchner A; Schlapschy M; Datar R; Binder U; Edwards CK; Skerra A; Dinarello CA
    J Biol Chem; 2020 Jan; 295(3):868-882. PubMed ID: 31819009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local release of masitinib alters in vivo implantable continuous glucose sensor performance.
    Avula M; Jones D; Rao AN; McClain D; McGill LD; Grainger DW; Solzbacher F
    Biosens Bioelectron; 2016 Mar; 77():149-56. PubMed ID: 26402593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-kappaB activation and a reciprocal suppression of TGF-beta signal pathway.
    Ishida Y; Kondo T; Kimura A; Matsushima K; Mukaida N
    J Immunol; 2006 May; 176(9):5598-606. PubMed ID: 16622029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice.
    Lamacchia C; Palmer G; Bischoff L; Rodriguez E; Talabot-Ayer D; Gabay C
    J Immunol; 2010 Aug; 185(4):2516-24. PubMed ID: 20639493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis.
    Rogier R; Ederveen THA; Boekhorst J; Wopereis H; Scher JU; Manasson J; Frambach SJCM; Knol J; Garssen J; van der Kraan PM; Koenders MI; van den Berg WB; van Hijum SAFT; Abdollahi-Roodsaz S
    Microbiome; 2017 Jun; 5(1):63. PubMed ID: 28645307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking of interleukin-1 suppresses angiotensin II-induced renal injury.
    Akita K; Isoda K; Ohtomo F; Isobe S; Niida T; Sato-Okabayashi Y; Sano M; Shimada K; Iwakura Y; Minamino T
    Clin Sci (Lond); 2021 Sep; 135(17):2035-2048. PubMed ID: 34402864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 receptor antagonist originating from bone marrowderived cells and non-bone marrow-derived cells helps to suppress arterial inflammation and reduce neointimal formation after injury.
    Isoda K; Akita K; Isobe S; Niida T; Adachi T; Iwakura Y; Daida H
    J Atheroscler Thromb; 2014; 21(11):1208-18. PubMed ID: 25223697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines, prostaglandin E2 synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice.
    Mizutani H; Ishihara Y; Izawa A; Fujihara Y; Kobayashi S; Gotou H; Okabe E; Takeda H; Ozawa Y; Kamiya Y; Kamei H; Kikuchi T; Yamamoto G; Mitani A; Nishihara T; Noguchi T
    J Periodontal Res; 2013 Dec; 48(6):748-56. PubMed ID: 23586622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.
    Ricci S; Macchia G; Ruggiero P; Maggi T; Bossù P; Xu L; Medaglini D; Tagliabue A; Hammarström L; Pozzi G; Boraschi D
    BMC Biotechnol; 2003 Sep; 3():15. PubMed ID: 13129437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type I IL-1 receptor.
    Irikura VM; Lagraoui M; Hirsh D
    J Immunol; 2002 Jul; 169(1):393-8. PubMed ID: 12077269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basement Membrane-Based Glucose Sensor Coatings Enhance Continuous Glucose Monitoring in Vivo.
    Klueh U; Qiao Y; Czajkowski C; Ludzinska I; Antar O; Kreutzer DL
    J Diabetes Sci Technol; 2015 Aug; 9(5):957-65. PubMed ID: 26306494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CCL2 and CCR2 chemokine/receptor deficiencies on macrophage recruitment and continuous glucose monitoring in vivo.
    Klueh U; Czajkowski C; Ludzinska I; Qiao Y; Frailey J; Kreutzer DL
    Biosens Bioelectron; 2016 Dec; 86():262-269. PubMed ID: 27376197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.
    Hill-Batorski L; Halfmann P; Marzi A; Lopes TJ; Neumann G; Feldmann H; Kawaoka Y
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S329-35. PubMed ID: 26209680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
    McIntyre KW; Stepan GJ; Kolinsky KD; Benjamin WR; Plocinski JM; Kaffka KL; Campen CA; Chizzonite RA; Kilian PL
    J Exp Med; 1991 Apr; 173(4):931-9. PubMed ID: 1826128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.